
- Who
- Isomorphic Labs
- What
- announced $5 billion in funding to accelerate its AI drug design mission
- When
What happened
Isomorphic Labs has raised $5 billion in a Series C round to advance its drug candidates toward clinical trials. The funding was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and existing backers also participating. The company said its program has produced positive preclinical results in oncology and immunology; it plans to keep developing its drug-design engine and expand into more types of medicine.
Reported by 2 sources
The story so far
Isomorphic Labs has raised $5 billion in a Series C funding round to advance its drug candidates toward clinical trials. This capital was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and the company's existing investors. The AI drug-discovery platform, which spun out of Google's DeepMind in 2021, stated that it has already achieved positive preclinical results in oncology and immunology. CEO Demis Hassabis described the funding as a step toward the company's mission to use AI to "Solve All Disease," with the goal of radically reducing the time and cost required to discover new medicines. Following this investment, the company plans to continue developing its core drug-design engine and intends to expand its research into further types of medicine.
